Horizon Therapeutics Public Limited (NASDAQ:HZNP) CEO Timothy P. Walbert Sells 17,600 Shares

Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) CEO Timothy P. Walbert sold 17,600 shares of the stock in a transaction that occurred on Wednesday, May 11th. The stock was sold at an average price of $90.00, for a total value of $1,584,000.00. Following the completion of the transaction, the chief executive officer now directly owns 460,549 shares in the company, valued at approximately $41,449,410. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of HZNP stock opened at $90.43 on Friday. The company has a current ratio of 3.57, a quick ratio of 3.30 and a debt-to-equity ratio of 0.53. The firm has a fifty day moving average price of $104.33 and a 200 day moving average price of $102.04. The company has a market cap of $20.79 billion, a P/E ratio of 24.78, a PEG ratio of 1.23 and a beta of 1.11. Horizon Therapeutics Public Limited has a 12 month low of $82.51 and a 12 month high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.20. The firm had revenue of $885.25 million during the quarter, compared to the consensus estimate of $866.39 million. Horizon Therapeutics Public had a net margin of 22.87% and a return on equity of 32.08%. The company’s revenue was up 158.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.03 earnings per share. On average, equities analysts forecast that Horizon Therapeutics Public Limited will post 5.59 EPS for the current year.

Several hedge funds have recently modified their holdings of HZNP. Trust Investment Advisors boosted its stake in Horizon Therapeutics Public by 4.2% in the fourth quarter. Trust Investment Advisors now owns 2,922 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 117 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Horizon Therapeutics Public by 29.7% in the fourth quarter. Quadrant Capital Group LLC now owns 515 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 118 shares in the last quarter. CIBC World Markets Inc. boosted its stake in Horizon Therapeutics Public by 0.8% in the fourth quarter. CIBC World Markets Inc. now owns 15,439 shares of the biopharmaceutical company’s stock valued at $1,664,000 after acquiring an additional 119 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its stake in Horizon Therapeutics Public by 0.8% in the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 14,652 shares of the biopharmaceutical company’s stock valued at $1,605,000 after acquiring an additional 122 shares in the last quarter. Finally, Hancock Whitney Corp boosted its stake in Horizon Therapeutics Public by 4.3% in the fourth quarter. Hancock Whitney Corp now owns 3,081 shares of the biopharmaceutical company’s stock valued at $332,000 after acquiring an additional 127 shares in the last quarter. Hedge funds and other institutional investors own 88.39% of the company’s stock.

HZNP has been the topic of several recent research reports. Oppenheimer initiated coverage on Horizon Therapeutics Public in a research report on Monday, March 14th. They set an “outperform” rating and a $140.00 target price on the stock. Piper Sandler dropped their target price on Horizon Therapeutics Public from $143.00 to $133.00 in a research report on Wednesday, January 26th. Wells Fargo & Company reiterated a “buy” rating and set a $133.00 price objective on shares of Horizon Therapeutics Public in a report on Friday, April 8th. Morgan Stanley raised their target price on Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 2nd. Finally, StockNews.com started coverage on Horizon Therapeutics Public in a research note on Thursday, March 31st. They set a “hold” rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $133.67.

Horizon Therapeutics Public Company Profile (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Read More

Insider Buying and Selling by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.